Drug Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Drug Name axicabtagene ciloleucel
Trade Name Yescarta
Synonyms KTE-C19 CAR|KTE-C19
Drug Descriptions

Yescarta (axicabtagene ciloleucel) is an immunotherapy consisted of peripheral T-lymphocytes engineered to express a chimeric antigen receptor targeting CD19, CD28 and CD3zeta, resulting in immunostimulating and antineoplastic activities (PMID: 32401634). Yescarta (axicabtagene ciloleucel) is FDA approved for adult patients with large B-cell lymphoma who is refractory or relapsed on first-line chemoimmunotherapy or have received two or more lines of therapies, including diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma, and for adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of therapies, but is not indicated for patients with primary central nervous system lymphoma (FDA.gov).

CAS Registry Number NA
NCIT ID C120309


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Therapy Name Drugs Efficacy Evidence Clinical Trials
Acalabrutinib + axicabtagene ciloleucel Acalabrutinib axicabtagene ciloleucel 0 1
Anakinra + axicabtagene ciloleucel + Cyclophosphamide + Fludarabine Anakinra Cyclophosphamide Fludarabine axicabtagene ciloleucel 0 1
Atezolizumab + axicabtagene ciloleucel Atezolizumab axicabtagene ciloleucel 0 1
axicabtagene ciloleucel axicabtagene ciloleucel 0 10
axicabtagene ciloleucel + Cyclophosphamide + Dexamethasone + Fludarabine Cyclophosphamide Dexamethasone Fludarabine axicabtagene ciloleucel 0 1
axicabtagene ciloleucel + Cyclophosphamide + Fludarabine Cyclophosphamide Fludarabine axicabtagene ciloleucel 0 4
axicabtagene ciloleucel + Cyclophosphamide + Fludarabine + Lenalidomide Cyclophosphamide Fludarabine Lenalidomide axicabtagene ciloleucel 0 0
axicabtagene ciloleucel + Cyclophosphamide + Fludarabine + Rituximab Cyclophosphamide Fludarabine Rituximab axicabtagene ciloleucel 0 1
axicabtagene ciloleucel + Lenzilumab Lenzilumab axicabtagene ciloleucel 0 1
axicabtagene ciloleucel + Utomilumab Utomilumab axicabtagene ciloleucel 0 1

Additional content available in CKB BOOST